New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Is it beginning to look a lot like Christmas? I ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Fans have asked, and the Minnesota Timberwolves have finally answered: The trees are back in Minnesota. The Kevin Garnett-era jersey and court — which were most known for their green tree-lined trim — ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Good programmers need to create code that efficiently solves problems, using various methods. A ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...